Diagnosing Merck (Part 1 Of 2)

MRK has chopped horizontally for over a year, after surging on news of a major clinical trial failure for a competitor's product. This failure involved the BMY drug Opdivo, leaving MRK's Keytruda alone for frontline use for many lung cancer patients.

Source : https://seekingalpha.com/article/4101087-diagnosing-merck-part-1-2

105